Medical expert of the article
New publications
Antibodies to hepatic-specific lipoprotein in the blood
Last reviewed: 18.10.2021
All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.
We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.
If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.
Normally, antibodies to liver-specific lipoprotein in serum are absent.
Antibodies to liver-specific lipoprotein are determined by the method of indirect immunofluorescence. Hepatic-specific lipoprotein (LSP) is a heterogeneous material from hepatocyte membranes, containing 7-8 antigenic determinants, some of them are hepatic-specific, others are nonspecific. It is the antibodies to the liver-specific lipoprotein that cause an autoimmune reaction with the development of antibody-dependent cytolysis of hepatocytes and provoke a relapse with the abolition of glucocorticosteroids in patients with chronic autoimmune hepatitis. The presence of antibodies to liver-specific lipoprotein in the blood serum is a hallmark of autoimmune hepatitis. Nevertheless, it is established that they appear in chronic liver diseases of viral etiology (in 48-97% of cases).
[1], [2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15]